which is difficult to observe by computer simulations, is the wide range of aggregation scenarios emerging from a variety of biophysical measurements 21, 22 . Atomistic models have been employed to study the conformational space of amyloidogenic polypeptides in the monomeric state 23-25 , the very initial steps of amyloid formation [26] [27] [28] [29] [30] [31] [32] , and the structural stability of fibril models [33] [34] [35] . However, all-atom simulations of the kinetics of fibril formation are beyond what can be done with modern computers.
To overcome such computational limitations, simplified models have been developed and used to investigate the kinetics and pathways of oligomerization and fibril formation at different levels of resolution 36 . In this chapter we first review briefly the simplified models of aggregation. We then present our coarse-grained phenomenological (CGF) model of an amphipathic peptide 37 , and its use for studying kinetics and thermodynamics, both in bulk conditions and in presence of other simplified (macro)molecules.
II. COARSE-GRAINED MODELS
In coarse-grained models, the complexity of a system (and therefore the computational cost) is reduced by grouping atoms into larger units or "beads", whose mutual interactions are usually approximated by a potential of mean force 38 . Several coarse-
A. Aggregation kinetics and pathways
The range of aggregation kinetics of the CGF model is shown in The distribution function p(N ) of the oligomer size N evaluated at the lag phase orat the final equilibrium is depicted in Fig. 5 . The monomer peak ranges from N = 1 to N = 7, the micellar peak from N = 8 to N = 60, and the fibrillar peak from N = 61
to N = 125. The micellar peak is present for the dE = -2.5 kcal/mol model at the lag phase, but disappears at the final equilibrium, where the fibril and the monomers are the only co-existing species. For the β-stable potential dE = 0.0 kcal/mol, the micellar peak is not observed at any concentration value. Indeed, a comparison of the lag times with the times of micelle formation (Fig. 6) shows that the fibril formation kinetics of the β-unstable and β-stable models are, respectively, slower and faster than micelle formation.
In fact, micelles are intermediates consisting mainly of monomers in the π state, whereas the polymerization of β-stable monomers directly yields fibrils.
This observation is confirmed also by the analysis of aggregation pathways 50 . A total of 100 Langevin dynamics simulations for different values of dE were clustered according to three progress variables: the size of the largest aggregate N la , the number of monomers in the β-state within the largest aggregate N β la , and the number of protofilaments in the largest aggregate N pf la , where a protofilament is defined as a file of monomers with intermolecular dipolar interactions parallel with its axis. The aggregation state network (Fig. 7) is a graph in which the states and direct transitions observed during the Langevin dynamics simulations are displayed as nodes and links, respectively. Furthermore, the size of each node reflects the statistical weight of the corresponding state. Micellar oligomers (white nodes, N la ∼ 20, N pf la =0) and fibrils (red nodes, N la ∼ 100, N pf la =4) are the most populated states during the lag phase and the final equilibrium, respectively. Strikingly, a greater variety of aggregation mechanisms emerges for the poorly amyloidogenic CGF peptide model (see Fig. 7 , bottom) than the highly amyloidogenic CGF peptide model (see Fig. 7, top) . Indeed, the former shows the presence of intermediates, i.e., protofibrils consisting of only two (green nodes) or three (blue nodes) protofilaments. According to this analysis, it is reasonable to expect that a mutation that decreases the β-aggregation tendency could result in a greater variety of prefibrillar aggregates, as in the case of the Arctic mutant (E22G) of the Alzheimer's Aβ peptide and the A30P mutant for α-synuclein, for which a more pronounced in vitro formation of oligomers and protofibrils was observed 51,52 .
B. Mechanism of nucleation
The nucleation properties of the CGF model are investigated by evaluating the probability of fibril formation for β-subdomains, i.e., the clusters of interacting β-monomers.
The nucleus, defined as the oligomer containing a β-subdomain with a 50% probability to form a fibril, shows an increasing size upon destabilization of the β-state. Significantly different nucleation mechanisms are observed upon variation of the amyloidogenicity parameter dE (Fig. 8) 
C. Concentration effects
The dE parameter of the CGF model has a strong influence on the concentration dependence of the fibril formation kinetics. In agreement with the above-mentioned mechanism of nucleation, CGF peptides poorly prone to aggregation nucleate only at concentration values larger than the critical concentration of peptide micelle formation, whereas CGF peptides with a high value of amyloidogenicity nucleate even at lower concentrations (Fig. 9, left) . Furthermore, the dependence of the elongation rate on the concentration is only marginal at low amyloidogenic tendency (Fig. 9 (b) ). by the amyloidogenic propensity dE, and two main mechanisms for fibril morphogenesis emerge. When the CGF peptide is highly prone to aggregate (dE = -1.5, -2.0 kcal/mol), the morphogenesis is under thermodynamic control, meaning that the morphology with the highest stability will emerge with the highest probability. In contrast, when the CGF peptide has a low amyloidogenic tendency (dE = -2.25, -2.5 kcal/mol), the fibril morphogenesis is under kinetic control. The morphologies that nucleate more readily are not necessarily the most stable ones, but those whose precursors are kinetically more accessible, as revealed by the free energy profiles of the fibrillation 64 . For the low amyloidogenic scenario, the process of morphology differentiation can be represented by a branched tree (Fig. 10 ). During the lag phase, the micellar oligomers are in equilibrium with the dispersed monomers. The early morphology differentiation occurs at the nucleation step, where the formation of the protofibrillar intermediates is regulated by the structural bifurcation of the nucleus. The 2PP and 3PP1 intermediates are competent to 4PF1 fibrils, while the 3PP2 intermediate is competent to 4PF2(+,-) fibrils. Alternatively, the presence of 3PP2+ and 3PP2-intermediates that are directly competent to 4PF2+ and 4PF2-fibrils, respectively, has been observed, although these pathways were not quantitatively analyzed. Finally, the pathway of formation of 4PF3 fibrils was not investigated in detail, due to the small number of nucleation events of this morphology.
The multiple-pathways process observed here has a close similarity with the scenario described by Goldsbury et al. 65 , where two different morphologies of Aβ have distinct maturation pathways, either with or without the presence of metastable protofibrils.
V. AGGREGATION IN THE PRESENCE OF LIPID VESICLES AND INERT

CROWDERS
Amyloid aggregation in vivo does not occur in bulk solution. Rather, it takes place in the extracellular space, whose composition includes metabolites and proteins, or within the cell, which is usually densely occupied by (macro)molecules like proteins, nucleic acids, and polysaccharides, as well as macromolecular assemblies and organelles 66 . Several research groups have investigated the interactions between lipid vesicles and amyloid aggregates [67] [68] [69] , whose accumulation on the surface of lipid bilayers was observed to cause membrane damage. Aggregation has also been studied in crowded media [70] [71] [72] , where the thermodynamics and kinetics of aggregation are expected to sensibly change.
A. Effect of lipid bilayers on CGF peptide aggregation
A three-bead model of a lipid molecule has been developed to study the CGF peptide der Waals coupling parameter λ, between 50% and 80% of the CGF peptides are located on the lipid vesicle surface after the initial equilibration phase, i.e., before fibril formation (Table 1 ).
The effect of lipid bilayers on aggregation kinetics for different values of amyloidogenicity is reported in Table 2 . Highly amyloidogenic peptides fibrillate more rapidly in the presence of lipid vesicles than in their absence, while the opposite is observed for peptides of low amyloidogenicity. The faster aggregation kinetics of highly amyloidogenic peptides is a consequence of their higher effective concentration on the lipid bilayer relative to the bulk. In contrast, despite the same increase of peptide concentration on the vesicle surface, fibrillation of peptides with low amyloidogenic propensity is slower in the presence of lipid vesicles. As mentioned in section III, peptides with low amyloidogenic potential can fibrillate only after aggregating into spherical oligomeric intermediates with hydrophobic interior and hydrophilic surface. In the simulations with lipids, such oligomeric intermediates form in the bulk but not on the vesicle. Fibrillation of low amyloidogenic peptides therefore takes place in the bulk and is slower than in the absence of a vesicle due to the lower effective concentration of peptides in the solvent. These simulation results areconsistent with and explain the apparently contradictory experimental observations on faster aggregation of the Aβ(Ref. 68 ) or α-synuclein 75 peptides in the presence of lipid surfaces and slower aggregation of insulin (which has lower amyloidogenicity) 76 , and have been confirmed by recent studies on the aggregation properties of human islet amyloid polypeptide hIAPP 1−19 in presence of lipid vesicles 77 .
To investigate the influence of the CGF peptides on the lipid bilayer, the simulations were initiated with 20 spherical probes inside the vesicle. It was observed that leakage from the lipid vesicle is enhanced during fibril formation but not by the mature fibril 73 .
More precisely, a comparison between the fibrillation and probe release rates (Fig. 11, left) revealed that probe release is fastest during fibril growth, whereas the kinetics of probe release in the presence of mature fibrils is as slow as in the absence of peptides, indicating that mature fibrils do not damage the integrity of the vesicle. Rather, the (Fig. 11 right) .
It has also been hypothesized that formation of toxic oligomers that induce membrane leakage could be the result of a backward production of oligomers from the mature fibril 79 .
Interestingly, by modulating the attraction between the CGF peptides and the membrane, fibril disaggregation into soluble backwards oligomers has been observed 74 . The disaggregation process is driven by entropy and results in soluble protofibrillar oligomers. The protofibrillar oligomers are larger, more ordered, and more stable than those observed during the aggregation process and, importantly, are not detected in disaggregation simulations carried out in bulk solution, i.e., in the absence of lipid vesicles.
B. Effect of surfactants on CGF peptide aggregation
Surfactant molecules have been modeled using a similar three-bead model as that used for lipids. The surfactant model differs from lipid models used previously in two parameters (Table 1) : the minimum of the van der Waals energy of the two hydrophobic beads is less favorable, and the radius of the hydrophilic bead is larger to enable the formation of amorphous aggregates. Using these parameters, the surfactant solution is not dominated by a micellar phase. Rather, the surfactants are organized either asdispersed monomers or disordered aggregates 80 .
In the absence of surfactants, all peptide models form fibrils within 1 µs without any discernible lag phase (Fig. 12, dotted lines) . At a surfactant:peptide ratio of 8:1, the fibril formation kinetics of peptides with dE = -1.5 kcal/mol are almost unaffected, whereas already at a ratio of 4:1 the ordered self-assembly of peptides with dE < -2.0 kcal/mol is significantly slower (Fig. 12, solid lines) mainly because of a longer lag phase. Moreover, for low-amyloidogenic peptides (dE ≤ -2.0 kcal/mol) no fibrillation is observed within the simulation length of 2 µs at a surfactant:peptide ratio of 8:1, but instead oligomers of ∼ 40 peptides form. These simulation results show that at a 4-fold molar excess of surfactant, the inhibition of fibrillation already depends strongly on the amyloidogenicity of the CGF peptide model.
C. Macromolecular crowding effect on CGF peptide aggregation
Simulations with the CGF peptide model together with softly repulsive spheres have been carried out to assess the influence on the aggregation kinetics of excluded volume and hindered peptide diffusion due to macromolecular crowding 81 . As in the case of lipid-bilayer vesicles, the net effect of macromolecular crowding crucially depends on the amyloidogenicity tendency of the CGF peptide. For peptides with low aggregation propensity, the self-association process is transition-state limited, where the kinetic bottleneck is the formation of the fibril nucleus. In this case, since the oligomers, including the nucleus, are thermodynamically favored (with respect to the isolated monomers) by the excluded volume effect, macromolecular crowding accelerates peptide assembly and has an effect analogous to that of an increase in peptide concentration (Fig. 13, left) .
This trend is analogous to that observed experimentally by Munishkina et al., who have studied the effect of increasing the PEG concentration on the α-synuclein aggregation process 71 .
On the other hand, when the aggregation mechanism is fast and proceeds directly from monomers to fibril, the process is diffusion limited, and the thermodynamic stabilization of oligomers is less important than the reduction in peptide mobility. In this case, the bottleneck is not the formation of the nucleus; the rate-limiting step for peptides that show a direct aggregation mechanism is the elongation of the fibril. Therefore, in this case macromolecular crowding is much less efficient in accelerating the self-association of peptides than an equivalent increase in peptide concentration, since the peptides diffusion is hindered by the crowders (Fig.13, right) .
VI. CONCLUSION
Atomistic simulations of aggregation are limited by short time scale, while experimental approaches to amyloid fibril formation have insufficient spatial resolution. Coarsegrained models of polypeptide aggregation sacrifice atomistic detail to reach timescales that allow the comparison with and interpretation of experimental data. The models presented in this chapter have shed light upon amyloid aggregation kinetics and mechanisms, which is helpful to formulate a unified picture of the available experimental data.
The CGF model has only one tunable parameter, the difference dE between the energy of the amyloid-competent and the amyloid-protected state of the monomer 37 . Variations of this parameter reproduce several aggregation scenarios, both under homogeneous and heterogeneous conditions. It is important to highlight that the CGF model does not mimic any particular amyloid (poly)peptide sequence. However, the different aggregation kinetics obtained with this model can be directly compared with experiments carried out with specific proteins. In Table 3 are reviewed the principal characteristics of the aggregation process for both the high and low amyloidogenic tendency, and in both cases several examples of real amyloid-forming (poly)peptide sequences are listed. It is important to note that (coarse-grained) simulations, e.g., those with the CGF 37 and Shea small nucleus large nucleus [37] fast fibril formation slow fibril formation [37] downhill micellar intermediates [37] no intermediates protofibrillar intermediates [50] single pathway multiple pathways [50] strong concentration dependence growth rate marginally dependent on concentration [37] polymorphism under thermodynamic control polymorphism under kinetic control [64] can promote membrane leakage does not promote membrane leakage [73] slightly accelerated by membranes decelerated by membranes [73] marginally influenced by surfactants decelerated by surfactants [80] not accelerated by macromolecular crowding accelerated by macromolecular crowding [81] Phe-Phe, GNNQQNY, transthyretin, Aβ 42 Aβ 40 , Sup35, prion protein, myoglobin - 
